DiaMedica Therapeutics (DMAC) News Today $3.67 -0.23 (-5.90%) As of 03:59 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock DMAC Latest News All Sources Trusted Sources MarketBeat Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 Time Period Short Interest in DiaMedica Therapeutics Inc. (NASDAQ:DMAC) Expands By 38.3%DiaMedica Therapeutics Inc. (NASDAQ:DMAC - Get Free Report) was the recipient of a significant increase in short interest during the month of May. As of May 15th, there was short interest totalling 856,900 shares, an increase of 38.3% from the April 30th total of 619,700 shares. Currently, 2.2% of the company's shares are short sold. Based on an average daily volume of 93,700 shares, the short-interest ratio is presently 9.1 days.June 2, 2025 | marketbeat.comNorthern Trust Corp Has $978,000 Holdings in DiaMedica Therapeutics Inc. (NASDAQ:DMAC)Northern Trust Corp grew its holdings in shares of DiaMedica Therapeutics Inc. (NASDAQ:DMAC - Free Report) by 49.8% during the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 180,192 shares of the company's stock after buying an additional 59,May 31, 2025 | marketbeat.comDiaMedica Therapeutics (NASDAQ:DMAC) Earns "Buy" Rating from HC WainwrightHC Wainwright reissued a "buy" rating and set a $10.00 price target on shares of DiaMedica Therapeutics in a research report on Thursday.May 30, 2025 | marketbeat.comWith 39% ownership, DiaMedica Therapeutics Inc. (NASDAQ:DMAC) insiders have a lot riding on the company's futureMay 28, 2025 | finance.yahoo.comResearch Analysts Offer Predictions for DMAC FY2025 EarningsDiaMedica Therapeutics Inc. (NASDAQ:DMAC - Free Report) - Stock analysts at HC Wainwright boosted their FY2025 earnings per share (EPS) estimates for shares of DiaMedica Therapeutics in a research report issued on Thursday, May 15th. HC Wainwright analyst M. Caufield now forecasts that the companMay 21, 2025 | marketbeat.comDiaMedica Therapeutics Announces Key Opinion Leader Webinar on DM199 (Rinvecalinase Alfa) for the Treatment of PreeclampsiaMay 20, 2025 | finance.yahoo.comEarnings call transcript: DiaMedica Therapeutics Q1 2025 earnings beat expectationsMay 15, 2025 | investing.comDiaMedica Therapeutics Inc. (DMAC) Q1 2025 Earnings Call TranscriptMay 15, 2025 | seekingalpha.comDiaMedica Therapeutics Inc (DMAC) Q1 2025 Earnings Call Highlights: Strong Financial Position ...May 15, 2025 | finance.yahoo.comDiaMedica Therapeutics Announces Poster Presentation at European Stroke Organisation Conference – ESOC 2025May 14, 2025 | businesswire.comDiaMedica Therapeutics Reports First Quarter 2025 Financial Results And Provides Business HighlightsMay 13, 2025 | businesswire.comInsights Ahead: DiaMedica Therapeutics's Quarterly EarningsMay 12, 2025 | benzinga.comDiaMedica Therapeutics Inc. (NASDAQ:DMAC) Shares Acquired by Susquehanna International Group LLPSusquehanna International Group LLP lifted its holdings in DiaMedica Therapeutics Inc. (NASDAQ:DMAC - Free Report) by 269.5% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 374,845 shares of the company'May 12, 2025 | marketbeat.comDiaMedica Therapeutics (DMAC) Projected to Post Earnings on WednesdayDiaMedica Therapeutics (NASDAQ:DMAC) will be releasing its Q1 2025 earnings before the market opens on Wednesday, May 14. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2025-5-14-diamedica-therapeutics-inc-stock/)May 9, 2025 | marketbeat.comDiaMedica Therapeutics to Participate in Upcoming Investor Conferences in MayMay 8, 2025 | businesswire.com683 Capital Management LLC Buys New Shares in DiaMedica Therapeutics Inc. (NASDAQ:DMAC)683 Capital Management LLC bought a new position in shares of DiaMedica Therapeutics Inc. (NASDAQ:DMAC - Free Report) in the 4th quarter, according to its most recent Form 13F filing with the SEC. The fund bought 76,116 shares of the company's stock, valued at approximately $413,000. 683 Capital MaMay 5, 2025 | marketbeat.comWe're Hopeful That DiaMedica Therapeutics (NASDAQ:DMAC) Will Use Its Cash WiselyApril 25, 2025 | finance.yahoo.comDiaMedica Therapeutics Inc. (NASDAQ:DMAC) Short Interest UpdateDiaMedica Therapeutics Inc. (NASDAQ:DMAC - Get Free Report) was the target of a significant growth in short interest during the month of March. As of March 31st, there was short interest totalling 366,400 shares, a growth of 38.7% from the March 15th total of 264,200 shares. Approximately 0.9% of the company's shares are short sold. Based on an average trading volume of 90,200 shares, the days-to-cover ratio is presently 4.1 days.April 20, 2025 | marketbeat.comEquities Analysts Set Expectations for DMAC Q1 EarningsDiaMedica Therapeutics Inc. (NASDAQ:DMAC - Free Report) - Stock analysts at HC Wainwright issued their Q1 2025 EPS estimates for DiaMedica Therapeutics in a research report issued to clients and investors on Wednesday, March 19th. HC Wainwright analyst M. Caufield expects that the company will poMarch 22, 2025 | marketbeat.comDiaMedica Therapeutics (NASDAQ:DMAC) Price Target Raised to $10.00 at HC WainwrightHC Wainwright raised their price target on DiaMedica Therapeutics from $7.00 to $10.00 and gave the company a "buy" rating in a research report on Wednesday.March 20, 2025 | marketbeat.comDiaMedica Therapeutics price target raised to $10 from $7 at H.C. WainwrightMarch 20, 2025 | markets.businessinsider.comDiamedica Therapeutics (DMAC) Gets a Buy from Lake StreetMarch 20, 2025 | markets.businessinsider.comDiaMedica Therapeutics Inc. (NASDAQ:DMAC) Q4 2024 Earnings Call TranscriptMarch 19, 2025 | msn.comDiaMedica Therapeutics (NASDAQ:DMAC) Announces Earnings ResultsDiaMedica Therapeutics (NASDAQ:DMAC - Get Free Report) issued its quarterly earnings results on Monday. The company reported ($0.18) EPS for the quarter, missing the consensus estimate of ($0.17) by ($0.01).March 18, 2025 | marketbeat.comDiaMedica Therapeutics reports FY24 EPS (60c), consensus (59c)March 17, 2025 | markets.businessinsider.comDiaMedica Therapeutics Provides a Business Update and Announces Full Year 2024 Financial ResultsMarch 17, 2025 | businesswire.comInsider Stock Buying Reaches US$9.00m On DiaMedica TherapeuticsMarch 17, 2025 | finance.yahoo.comDiaMedica Therapeutics to Report Fourth Quarter 2024 Financial Results and Provide a Business Update March 18, 2025March 11, 2025 | businesswire.comDiaMedica Therapeutics (DMAC) to Release Quarterly Earnings on TuesdayDiaMedica Therapeutics (NASDAQ:DMAC) will be releasing earnings before the market opens on Tuesday, March 18, Financial Modeling Prep reports.March 11, 2025 | marketbeat.comShort Interest in DiaMedica Therapeutics Inc. (NASDAQ:DMAC) Grows By 21.1%DiaMedica Therapeutics Inc. (NASDAQ:DMAC - Get Free Report) was the recipient of a large growth in short interest in February. As of February 15th, there was short interest totalling 232,300 shares, a growth of 21.1% from the January 31st total of 191,900 shares. Based on an average trading volume of 113,800 shares, the short-interest ratio is presently 2.0 days.March 7, 2025 | marketbeat.comDiaMedica Therapeutics Appoints Daniel J. O’Connor to the Board of DirectorsFebruary 24, 2025 | finance.yahoo.comDiaMedica Therapeutics publishes DM199 data in StrokeFebruary 21, 2025 | markets.businessinsider.comCraig-Hallum Sticks to Their Buy Rating for Diamedica Therapeutics (DMAC)February 21, 2025 | markets.businessinsider.comDiaMedica Therapeutics Announces Publication of DM199’s Mechanism of Action for the Treatment of Acute Ischemic Stroke (AIS) in the Journal StrokeFebruary 20, 2025 | finance.yahoo.comShort Interest in DiaMedica Therapeutics Inc. (NASDAQ:DMAC) Drops By 8.4%DiaMedica Therapeutics Inc. (NASDAQ:DMAC - Get Free Report) was the target of a significant drop in short interest during the month of January. As of January 31st, there was short interest totalling 191,900 shares, a drop of 8.4% from the January 15th total of 209,500 shares. Based on an average daily volume of 103,200 shares, the short-interest ratio is currently 1.9 days.February 18, 2025 | marketbeat.comDiaMedica Therapeutics to Present at the Oppenheimer 35th Annual Healthcare Life Sciences ConferenceFebruary 11, 2025 | finance.yahoo.comDiaMedica Therapeutics Inc. (NASDAQ:DMAC) Sees Significant Increase in Short InterestDiaMedica Therapeutics Inc. (NASDAQ:DMAC - Get Free Report) was the target of a large growth in short interest in January. As of January 15th, there was short interest totalling 222,800 shares, a growth of 14.5% from the December 31st total of 194,600 shares. Based on an average daily trading volume, of 93,700 shares, the days-to-cover ratio is presently 2.4 days.February 1, 2025 | marketbeat.comDiaMedica Therapeutics (NASDAQ:DMAC) Shares Down 1.5% - Time to Sell?DiaMedica Therapeutics (NASDAQ:DMAC) Shares Down 1.5% - Here's What HappenedFebruary 1, 2025 | marketbeat.comDiaMedica Therapeutics Inc. (NASDAQ:DMAC) Short Interest Up 28.4% in DecemberDiaMedica Therapeutics Inc. (NASDAQ:DMAC - Get Free Report) was the recipient of a large growth in short interest in December. As of December 15th, there was short interest totalling 194,600 shares, a growth of 28.4% from the November 30th total of 151,500 shares. Based on an average trading volume of 87,500 shares, the days-to-cover ratio is presently 2.2 days.December 29, 2024 | marketbeat.comIndividual investors are DiaMedica Therapeutics Inc.'s (NASDAQ:DMAC) biggest owners and were hit after market cap dropped US$26mDecember 19, 2024 | uk.finance.yahoo.comAnalysts Offer Insights on Healthcare Companies: Qiagen (QGEN) and Diamedica Therapeutics (DMAC)December 18, 2024 | markets.businessinsider.comShort Interest in DiaMedica Therapeutics Inc. (NASDAQ:DMAC) Declines By 12.2%DiaMedica Therapeutics Inc. (NASDAQ:DMAC - Get Free Report) was the recipient of a significant drop in short interest in November. As of November 30th, there was short interest totalling 151,500 shares, a drop of 12.2% from the November 15th total of 172,500 shares. Based on an average daily trading volume, of 83,100 shares, the short-interest ratio is presently 1.8 days.December 15, 2024 | marketbeat.comDiaMedica Therapeutics (NASDAQ:DMAC) Trading 0.6% Higher - Should You Buy?DiaMedica Therapeutics (NASDAQ:DMAC) Trading Up 0.6% - Should You Buy?December 7, 2024 | marketbeat.comEnhanced Prospects for Diamedica Therapeutics with Trial Refinements and New InitiativesNovember 16, 2024 | markets.businessinsider.comDiaMedica Therapeutics (NASDAQ:DMAC) Given Buy Rating at HC WainwrightHC Wainwright reiterated a "buy" rating and issued a $7.00 price target on shares of DiaMedica Therapeutics in a report on Friday.November 15, 2024 | marketbeat.comDiaMedica Therapeutics Inc. (DMAC) Q3 2024 Earnings Call TranscriptNovember 14, 2024 | seekingalpha.comDiaMedica Therapeutics doses first patient in Phase 2 DM199 trialNovember 14, 2024 | markets.businessinsider.comDiaMedica Therapeutics Provides a Business Update and Announces Third Quarter 2024 Financial ResultsNovember 13, 2024 | businesswire.comDiaMedica Therapeutics Announces Dosing of First Patient in Phase 2 Trial of DM199 in the Treatment of PreeclampsiaNovember 13, 2024 | finance.yahoo.comDiaMedica Therapeutics Announces Dosing of First Patient in Phase 2 Trial of DM199 in the Treatment of PreeclampsiaNovember 13, 2024 | businesswire.com Get DiaMedica Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for DMAC and its competitors with MarketBeat's FREE daily newsletter. Email Address DMAC Media Mentions By Week DMAC Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. DMAC News Sentiment▼0.430.88▲Average Medical News Sentiment DMAC News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. DMAC Articles This Week▼21▲DMAC Articles Average Week Get DiaMedica Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for DMAC and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies AnaptysBio News Xencor News Anavex Life Sciences News Arbutus Biopharma News Sana Biotechnology News Trevi Therapeutics News Bicara Therapeutics News Autolus Therapeutics News Evolus News Phathom Pharmaceuticals News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:DMAC) was last updated on 6/13/2025 by MarketBeat.com Staff From Our PartnersElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredAn AI run of epic proportions is only getting startedI just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredWe’ve Entered the Most Bullish Phase of the CycleIt happens like clockwork. Every four years, the crypto market enters a new phase — and for those who know how...Crypto Swap Profits | SponsoredWhy Elon put $51 million into thisWhy Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT ScientistsTrue Market Insiders | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Something big is brewing in Washington. According to my research, an executive order from President Trump c...Weiss Ratings | SponsoredSilicon Valley Gold RushA new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredCollect $7k per month from Tesla’s SECRET dividendI just uncovered a strategy that could pay out up to $7,013 every month—without needing a traditional dividend...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding DiaMedica Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share DiaMedica Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy DMAC Stock Free DMAC Stock Alerts